| TQ0010 |
Brepocitinib
|
1883299-62-4
|
98%
|
|
|
Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).
|
| T2S1040 |
Jolkinolide B
|
37905-08-1
|
98%
|
|
|
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud. Jolkinolide B induces apoptosis in cancer cells. Jolkinolide B can...
|
| T2S1975 |
Ponicidin
|
52617-37-5
|
98%
|
|
|
Ponicidin (Rubescensine B) is a diterpenoid derived from Rabdosia rubescens. Ponicidin exhibits immunoregulatory, anti-inflammatory, anti-viral, and anti-cancer ...
|
| T35900 |
JAK2-IN-7
|
2593402-36-7
|
98%
|
|
|
JAK2-IN-7, a selective inhibitor targeting Janus Kinase 2 (JAK2), exhibits inhibitory concentrations (IC50) of 3 nM for JAK2, 11.7 nM for SET-2 cells, and 41 nM ...
|
| T61494 |
JAK-IN-21
|
2445499-20-5
|
98%
|
|
|
JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.
|
| T67907 |
Nimucitinib
|
2740557-24-6
|
98%
|
|
|
Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.
|
| T9826 |
GDC-0214
|
1831144-46-7
|
98%
|
|
|
GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).
|
| T40443 |
JAK2-IN-6
|
353512-04-6
|
98%
|
|
|
JAK2-IN-6, a polysubstituted aminothiazole derivative, is a potent and selective inhibitor of JAK2 (ic50 at 22.86 μg/mL). Jak2-in-6 inhibits the activity of JAK2...
|
| T77672 |
JI069
|
850019-35-1
|
98%
|
|
|
JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.
|
| T38624 |
Fosifidancitinib
|
1237168-58-9
|
98%
|
|
|
Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.
|
| T17019 |
TCS 21311
|
1260181-14-3
|
|
|
|
TCS 21311 (NIBR3049) is an effective and highly selective inhibitor of JAK3 (IC50: 8 nM). TCS 21311 inhibits PKCα, PKCθ, and GSK3β (IC50s: 13, 68, and 3 nM, resp...
|
| T3042 |
JAK2 Inhibitor V
|
195371-52-9
|
|
|
|
JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.
|
| T3620 |
Solcitinib
|
1206163-45-2
|
|
|
|
Solcitinib (GLPG-0778) (GSK2586184, GLPG0778) is a JAK1 inhibitor. Solcitinib may be potentially used for the treatment of psoriasis, ulcerative colitis, and sys...
|
| T6145 |
ZM39923 hydrochloride
|
1021868-92-7
|
|
|
|
ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be ...
|
| T3024 |
Avitinib
|
1557267-42-1
|
100%
|
|
|
Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, wi...
|
| TJS1779 |
Protosappanin A
|
102036-28-2
|
100%
|
|
|
Protosappanin A (PTA) has anti-oxidative/nitrative activities on brain immune and neuroinflammation through regulation of CD14/TLR4-dependent IKK/IκB/NF-κB inf...
|
| T4672 |
Brevilin A
|
16503-32-5
|
100%
|
|
|
Brevilin A is a sesquiterpene lactone isolated from Centipeda minima, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells with anti-tumor a...
|
| T6266 |
PP2
|
172889-27-9
|
95.65%
|
|
|
PP2 (AG 1879,AGL 1879) is a effective inhibitor of Lck/Fyn (IC50:4/5 nM) , ~100-fold less potent to EGFR, inactive for ZAP-70, PKA and JAK2.
|
| T6838 |
FLLL32
|
1226895-15-3
|
96.39%
|
|
|
FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).
|
| T2378 |
RGB-286638 free base
|
784210-88-4
|
97.29%
|
|
|
RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3...
|
